Search Within

Malin Lisa Hultcrantz

Formats
  1. Meeting Abstract (171)
  2. Journal Article (68)
  3. Research Letter (9)
  4. Guidelines (6)
  5. Review (3)
  6. Correspondence (2)
  7. Book Section (1)
Groups
  1. Center for Hematologic Malignancies (260)
  2. Department of Medicine (260)
  3. Hematologic Malignancies, Division of (260)
  4. Myeloma (260)
  5. Sloan Kettering Institute Postdocs (260)
  6. Hematologic Malignancies Research (179)

More Groups

People
  1. Sham Mailankody (148)
  2. Neha Korde (145)
  3. Alexander Lesokhin (140)
  4. Hani Hassoun (135)
  5. Urvi Shah (125)
  6. Heather Landau (119)

More People

Years
  1. 2025 (8)
  2. 2024 (39)
  3. 2023 (51)
  4. 2022 (52)
  5. 2021 (30)
  6. 2020 (26)

More Years

Publications
  1. Blood (97)
  2. Clinical Lymphoma, Myeloma and Leukemia (50)
  3. Journal of Clinical Oncology (17)
  4. Blood Cancer Journal (13)
  5. Haematologica (10)
  6. Blood Advances (6)

More Publications

Publishers
  1. American Society of Hematology (103)
  2. Elsevier Inc. (55)
  3. Nature Publishing Group (21)
  4. American Society of Clinical Oncology (17)
  5. Ferrata Storti Foundation (10)
  6. American Association for Cancer Research (6)

More Publishers

Results (260)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma
    Journal Article

    Eveillard, M.; Rustad, E.; Roshal, M.; Zhang, Y.; Ciardiello, A.; Korde, N.; Hultcrantz, M.; Lu, S.; Shah, U.; Hassoun, H.; more...
    British Journal of Haematology (2020)

    Fulltext@MSK | Save
  • Incidence of myeloproliferative neoplasms – Trends by subgroup and age in a population-based study in Sweden
    Journal Article

    Hultcrantz, M.; Ravn Landtblom, A.; Andréasson, B.; Samuelsson, J.; Dickman, P. W.; Kristinsson, S. Y.; Björkholm, M.; Andersson, T. M. L.
    Journal of Internal Medicine (2020)

    Fulltext@MSK | Save
  • Moving from cancer burden to cancer genomics for smoldering myeloma: A review
    Review

    Maura, F.; Bolli, N.; Rustad, E. H.; Hultcrantz, M.; Munshi, N.; Landgren, O.
    JAMA Oncology (2020)

    Fulltext@MSK | Save
  • Genomic profiling of multiple myeloma: New insights and modern technologies
    Review

    Hultcrantz, M.; Yellapantula, V.; Rustad, E. H.
    Best Practice and Research: Clinical Haematology (2020)

    Fulltext@MSK | Save
  • Phase I study of selinexor, ixazomib, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma
    Research Letter

    Salcedo, M.; Lendvai, N.; Mastey, D.; Schlossman, J.; Hultcrantz, M.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Hemoglobin concentration and risk of arterial and venous thrombosis in 1.5 million Swedish and Danish blood donors
    Journal Article

    Hultcrantz, M.; Modlitba, A.; Vasan, S. K.; Sjölander, A.; Rostgaard, K.; Landgren, O.; Hjalgrim, H.; Ullum, H.; Erikstrup, C.; Kristinsson, S. Y.; more...
    Thrombosis Research (2020)

    Fulltext@MSK | Save
  • VTE rates and safety analysis of newly diagnosed multiple myeloma patients receiving carfilzomib-lenalidomide-dexamethasone (KRD) with or without rivaroxaban prophylaxis
    Meeting Abstract

    Piedra, K. M.; Hassoun, H.; Buie, L. W.; Devlin, S. M.; Flynn, J.; Hultcrantz, M.; Lesokhin, A. M.; Lu, S. X.; Mailankody, S.; Shah, U. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • An observational, retrospective analysis of retreatment with carfilzomib in the management of patients with multiple myeloma
    Meeting Abstract

    Peterson, T. J.; Korde, N.; Hassoun, H.; Mailankody, S.; Lesokhin, A. M.; Hultcrantz, M.; Shah, U. A.; Smith, E. L.; Lu, S. X.; Landau, H. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow based flow cytometry for tracking measurable residual disease (MRD) in patients with multiple myeloma
    Meeting Abstract

    Eveillard, M.; Rustad, E. H.; Roshal, M.; Zhang, Y.; Ciardiello, A. K.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Smith, E. L.; Lesokhin, A. M.; more...
    Blood (2019)

    Fulltext@MSK | Save